Rising concern about an AI "death spiral" for overleveraged data center players is pushing investors to focus on AI models that solve real problems and can justify their computing costs. That is where Australian AI healthcare stocks come in. These companies apply algorithms to diagnoses, treatment decisions, and hospital workflows. This article walks through three candidates from our screener that show how this theme translates into real-world potential.
The stocks below are a starter set, and the full AI healthcare screen surfaced 4 more companies with equally compelling narratives that are not covered in this article. If you want to identify potential leaders early, go straight to the Transformative Artificial intelligence (AI) Healthcare Stocks screener to filter and analyze the highest-conviction plays.
ImExHS (ASX:IME)
Overview:ImExHS provides cloud-based medical imaging software and radiology services that generate labeled scan and report data used to build AI diagnostics.
Operations:The business generates about A$10 million from software and A$21 million from radiology services, almost entirely across Latin America.
Market Cap:A$17 million
ImExHS plugs directly into the screener theme by turning day-to-day radiology, cardiology, and pathology work into structured data that can power AI diagnostics at scale.
"The quarterly release indiates the company is getting through to profitability and cashflow sustainability. They also understand the challenge now is to drive the software sales and revenue much faster in 2026."
What happens if one unseen pressure on that transition quietly shifts the balance between solid margins and expensive AI infrastructure?
That quiet pressure point is exactly where the full narrative for ImExHS shows how ImExHS could decouple profitable software from heavy AI costs and why that tension may be mispriced.
Paragon Care (ASX:PGC)
Overview:Paragon Care distributes medical equipment and consumables across Asia-Pacific, including AI-driven imaging and diagnostic software that supports smarter hospital workflows.
Operations:The group generates about A$3.5 billion from ANZ and A$160 million from Asia, with sales concentrated in Australia and New Zealand.
Market Cap:A$240 million
Paragon Care gives you a broad healthcare distributor that also sits on the rails of AI-enabled imaging, where hospitals increasingly want software that helps clinicians spot disease earlier and run busier departments with fewer bottlenecks.
"The integration of recent acquisitions and ongoing operational synergies (with a target of $12 million annual run-rate in FY '26), coupled with the consolidation of business functions onto a unified JDE platform, are likely to improve cost efficiencies and structurally enhance net margins and EBITDA."
The real test is whether one unresolved pressure on its balance sheet quietly decides how much of that AI opportunity reaches the bottom line.
That balance sheet pressure is exactly where the full narrative for Paragon Care pulls the story together, showing whether Paragon Care's AI push accelerates value or leaves returns stalling.
Artrya (ASX:AYA)
Overview:Artrya develops Salix, a cloud-based AI software suite that automatically analyzes coronary CT scans to assess heart attack risk.
Operations:The business currently generates about A$0.03 million from development of its AI-driven CCTA image analysis technology, all in Australia.
Market Cap:A$399.26 million
Artrya takes the screener theme and narrows it to a single high-stakes problem by using AI to read coronary CT scans and flag patients at risk before symptoms escalate.
"Growing adoption of CCTA as a front-line tool for chest pain assessment, together with up to 400,000 scans a year across SAPPHIRE partners at a blended rate of about US$850 per scan across three modules, gives Artrya a clear volume pathway that directly targets future subscription and fee per scan revenue."
What happens if one assumption inside that emerging volume story quietly shifts the balance between capital-heavy rollout and scalable software margins?
If that rollout risk matters to you, read the full narrative for Artrya to see how Artrya's volume pipeline could convert into scalable economics and where execution might stall.
Seeking Fresh Alternatives Beyond AI?
Fresh opportunities move fast, and by the time the crowd catches on, the best entry points can be gone. Scan these under-the-radar ideas while it matters and act now.
-
Target cash-generating outliers before momentum traders arrive by reviewing the curated 4 high quality undervalued stocks that still sit off most investors' radars.
-
Ride structural demand in digital infrastructure by scanning the curated 55 AI infrastructure stocks before capital chases the same limited group of enablers.
-
Tilt toward resilient balance sheets and steadier ride potential by filtering through the hand-picked 6 resilient stocks with low risk scores while prices still reflect hesitation, not conviction.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
